COMP <GO>
ISRG vs ABBV // NET PROFIT MARGIN
Intuitive Surgical Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ISRG 7
— ABBV 8
▲ NET PROFIT MARGIN LEADER: ISRG
LAST: $432.01 (-3.73%) • MKT CAP: $155.56B
net-margins
28.40%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ISRG VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ISRG | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.00% | 70.20% | -4.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.00% | 29.00% | -14.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 46.0x | 33.3x | +12.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.66% | 3.47% | -1.81 | ABBV | /fcf-yield <GO> |
| Operating Margin | 29.30% | 24.60% | +4.70 | ISRG | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 28.40% | 6.90% | +21.50 | ISRG | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | 8.60% | +11.90 | ISRG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | ISRG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | ISRG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | ISRG | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.1 | 72.8 | -18.63 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.15 | -0.18 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 113.1x | -67.30 | ISRG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $155.56B | $513.86B | -$358.30B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ISRG REV | ABBV REV | ISRG GROSS % | ABBV GROSS % | ISRG FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.06B | $61.16B | 66.0% | 70.2% | $2.58B | $17.82B |
| FY 2024 | $8.35B | $56.33B | 67.5% | 70.0% | $2.04B | $17.83B |
| FY 2023 | $7.12B | $54.32B | 44.0% | 44.0% | $1.49B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ISRG // BETA 0.97
ABBV // BETA 1.15